<!DOCTYPE html><html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"><meta name="format-detection" content="telephone=no"><meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no"><link rel="stylesheet" href="css/main.min.css"><script src="js/all.min.js"></script><script type="text/javascript">var slideNumber = 15</script></head><body class="s15"><div class="content-wrap"><nav><div onclick="iRep.go(1)" class="home-button"></div><ul><li onclick="iRep.go(3)" class="real-world-evidence"><span>REAL WORLD</span></li><li onclick="iRep.go(4)" class="evidence"><span>EVIDENCE</span></li><li onclick="iRep.go(12)" class="reversal"><span>REVERSAL</span></li><li onclick="iRep.go(14)" class="take-action"><span>COST</span></li><li onclick="iRep.goToolbox()" class="toolbox"><span>TOOLBOX</span></li><li onclick="iRep.go(16)" class="pi"><span>PI</span></li></ul></nav><div class="page-nav"><div onclick="iRep.nextSlide()" class="page-next"></div></div><article><div id="pop1" style="display:none" class="pop1"><div id="close" class="close-button"></div><div id="renal" class="renal"></div><div id="init" style="display:none" class="init"></div></div><h3>Pradaxa<sup>&reg;</sup>: Anticoagulate with confidence</h3><div class="bars"><div onclick="iRep.go(3)" class="bar1 blue"><div class="text"><span>The most independent real-world evidence of any NOAC, confirming the safety and efficacy of Pradaxa<sup>&reg;</sup> vs warfarin<sup>1-7</sup></span></div></div><div onclick="iRep.go(12)" class="bar2 blue"><div class="text"><span>The only NOAC with immediate reversal <br/> in rare emergency situations<sup>8-12</sup></span></div></div><div onclick="iRep.go(14)" class="bar3 blue"><div class="text"><span>Only £1.70 per day - lowest daily cost <br/> vs other NOACs<sup>13</sup></span></div></div><div onclick="iRep.go(12)" class="bar4 green"><div class="text"><span>Praxbind<sup>&reg;</sup> - The only NOAC reversal agent available in the UK until end 2017<sup>9,14</sup></span></div></div><div id="popup1" class="btn"><p>who will be your next<br/> <strong>pradaxa<sup>&reg;</sup> patient?</strong></p></div></div><div class="woman"></div></article><div class="overlay"></div><div class="sidebar"><ul><li class="references-tab tab"></li></ul><div class="panel"><div class="close-button"></div><div class="content references"><div class="text"><b>References: 1.</b> Graham DJ,<em> et al. Circulation</em> 2015;131:157-–64.<b> 2.</b> Larsen TB,<em> et al. Am J Med</em>  2014;127:650–656.<b> 3.</b> Larsen TB,<em> et al. Am J Med</em>  2014;127:329–336.<br/><b> 4.</b> Lauffenburger JC,<em> et al. J Am Heart Assoc</em>  2015;4:e001798.<b> 5.</b> Connolly SJ,<em> et al. N Engl J Med</em>  2009;361:1139–1151.<b> 6.</b> Connolly SJ,<em> et al. N Engl J Med</em>  <br/>2010;363:1875–1876.<b> 7.</b> Connolly SJ,<em> et al. N Engl J Med</em>  2014;371:1464–1465.<b> 8.</b> Boehringer Ingelheim. Pradaxa<sup>®</sup> Summary of Product Characteristics.<b> 9.</b> Boehringer <br/>Ingelheim. Praxbind<sup>®</sup> Summary of Product Characteristics.<b> 10.</b>  Schiele F<em>et al. Blood</em>  2013;121(18):3554–3562.<b> 11.</b> Sarich TC<em>et al. Am Heart J</em>  2015;169(6):751–757.<br/><b> 12.</b> Pollack CV<em> et al. N Engl J Med</em>  2015;373(6):511–520.<b> 13.</b> www.MIMS.co.uk [accessed May 2016].<b> 14.</b> Portola Pharmaceuticals, Inc., Corporate Update, January<br/> 2016, available at: http://investors.portola.comlphoenix.zhtml?c=198136&p=iroI-irhome. Accessed on 03/02/2016.</div></div></div></div><script>$('#popup1').on('click', function(){
    $('#pop1').show();
    $('.overlay').addClass('show');
});
$('#close').on('click', function(){
    $('#pop1').hide();
});
$('#renal').on('click', function(){
    $('#pop1').addClass('pop2');
    $(this).hide();
    $('#init').show();
});
$('#init').on('click', function(){
    $('#pop1').removeClass('pop2');
    $(this).hide();
    $('#renal').show();
});</script></div></body></html>